Eli Lilly and Co. announced plans to spend $400 million for the expansion of its manufacturing capabilities at its Indianapolis campus. The expansion project will include added capacity for its diabetes medicines, improvements to its current facilities that produce insulin, and initial capital investments for future drugs and therapies to be developed.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information
that is changing your industry today, hand-curated by our professional editors from
thousands of sources and delivered straight to your inbox.